Roche T + A immunotherapy research achieves historic breakthrough
2019-12-12
November 22, 2019, Roche announces data from positive studies of the IMbrave 150 phase III clinical trial aimed at treating liver cancer with Tecentriq (atelizumab) and Avastin (bevacizumab) combination therapy officially. The data shows that in patients with unresectable hepatocellular carcinoma (HCC) who have not previously received systemic treatment, Tecentriq and Avastin immunotherapy group patients achieved significant statistical and clinically significant improvements in overall survival (OS) and progression-free survival (PFS). IMbrave150 is a global phase III, multicenter, open-label study of 501 patients with unresectable hepatocellular carcinoma who have not previously received systemic therapy.
